

Personalised Solutions

*by Edwards Lifesciences— with the
broadest portfolio of therapies*

Personalised Touch

*by you, the physician— to deliver
optimal care for the most patients*



Together, we are making a meaningful mark on the lives of patients with mitral and tricuspid regurgitation




Edwards

Innovation for improved outcomes is what drives us. Now and in the future.


Mitral and tricuspid regurgitation are caused by compromised heart valves that allow blood to flow from the left ventricle to the left atrium and from the right ventricle to the right atrium, respectively.

These debilitating conditions affect more than 10% of people aged 65 and over in the US, creating a poor quality of life and high mortality rates. Yet fewer than 2% receive treatment intervention.*

*Based on 2010 US Census data and Stuge O, Liddicoat J. *J Thorac Cardiovasc Surg.* 2006;132:1258-1261.



That's why Edwards Transcatheter Mitral and Tricuspid Therapies (TMTT) group is committed to meeting the needs of this diverse and complex patient population by building a portfolio of transcatheter solutions. Each device is designed in close collaboration with HCPs, to address the personalised requirements of each patient.



At Edwards, we're
always innovating.

And none of our latest innovations
would be possible without our
close partnership with you.



For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, PASCAL, PASCAL Ace, Valtech, and Valtech Cardio are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP--EU-0518 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

To learn more about our portfolio of mitral
and tricuspid regurgitation solutions, visit
www.makeamark.com

